Benefits of HCV treatment in patients with hematologic malignancies
| Benefits of HCV treatment . |
|---|
| Infectious and hepatic |
| Prevention of long-term complications such as liver cirrhosis and end-stage liver disease |
| Prevention of hepatocellular carcinoma as a primary or secondary cancer in patients with chronic HCV infection |
| Improvement of long-term survival |
| Treatment of extrahepatic manifestations (cryoglobulinemia and fatigue) |
| Oncologic |
| Allowing patients access to multiple clinical trials of cancer chemotherapies, including trials of agents with hepatic metabolism |
| Prevention of some HCV-associated hematologic malignancies (eg, NHL) or decrease of the relapse rate of those malignancies |
| Cure of selected HCV-associated hematologic malignancies without chemotherapy |
| Benefits of HCV treatment . |
|---|
| Infectious and hepatic |
| Prevention of long-term complications such as liver cirrhosis and end-stage liver disease |
| Prevention of hepatocellular carcinoma as a primary or secondary cancer in patients with chronic HCV infection |
| Improvement of long-term survival |
| Treatment of extrahepatic manifestations (cryoglobulinemia and fatigue) |
| Oncologic |
| Allowing patients access to multiple clinical trials of cancer chemotherapies, including trials of agents with hepatic metabolism |
| Prevention of some HCV-associated hematologic malignancies (eg, NHL) or decrease of the relapse rate of those malignancies |
| Cure of selected HCV-associated hematologic malignancies without chemotherapy |